| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | <1 mi |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | <1 mi |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Phase 2 | Genentech, Inc. | <1 mi |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Phase 2 | AstraZeneca | <1 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection | Phase 2/3 | Bluejay Therapeutics, Inc. | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | Phase 1 | AbbVie | <1 mi |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Phase 2 | Coherus Oncology, Inc. | <1 mi |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | Inventiva Pharma | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | <1 mi |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | 89bio, Inc. | <1 mi |
| Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment | — | Fresenius Kabi | <1 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Phase 3 | Children's Oncology Group | <1 mi |
| A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | Phase 2 | Aligos Therapeutics | <1 mi |
| A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Phase 2 | Deciphera Pharmaceuticals, LLC | <1 mi |
| The Myelin Disorders Biorepository Project | — | Children's Hospital of Philadelphia | <1 mi |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | <1 mi |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | Children's Oncology Group | <1 mi |
| A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | Phase 1 | TORL Biotherapeutics, LLC | <1 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Phase 2 | Daiichi Sankyo | <1 mi |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | Phase 1/2 | Eisai Inc. | <1 mi |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study) | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | <1 mi |
| Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | Phase 1/2 | Qurient Co., Ltd. | <1 mi |
| Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | Phase 3 | Zydus Therapeutics Inc. | <1 mi |
| DILIN - Prospective Study | — | Duke University | <1 mi |
| Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema | Phase 2 | Sanofi | <1 mi |
| Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | <1 mi |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | — | Ipsen | <1 mi |
| CM for Patients With ALD After Liver Transplant | N/A | Arpan A. Patel, MD | <1 mi |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Ipsen | <1 mi |
| SAMe Trial for Patients With Alcoholic Cirrhosis | Phase 2 | Indiana University | <1 mi |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase 3 | Gilead Sciences | <1 mi |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | Mirum Pharmaceuticals, Inc. | <1 mi |
| PiMZ Longitudinal Cohort (PiMZ Logic) | — | Columbia University | <1 mi |
| A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment | — | Ipsen | <1 mi |
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease | Phase 2 | GlaxoSmithKline | <1 mi |
| A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 1 | Regeneron Pharmaceuticals | <1 mi |
| Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Phase 2 | Gilead Sciences | <1 mi |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | — | European Foundation for Study of Chronic Liver Failure | <1 mi |
| Genetic Collection Protocol | — | Arbor Research Collaborative for Health | <1 mi |
| Longitudinal Study of the Porphyrias | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial | — | Prime Medicine, Inc. | <1 mi |
| Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) | Phase 3 | Takeda | <1 mi |
| TReatment for ImmUne Mediated PathopHysiology | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | <1 mi |
| Drug-Induced Liver Injury (DILI) Network Retrospective | — | Duke University | <1 mi |
| Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients | — | University of California, Los Angeles | <1 mi |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Phase 3 | Takeda | <1 mi |
| An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency | Phase 1/2 | iECURE, Inc. | <1 mi |
| A Prospective Database of Infants With Cholestasis | — | Arbor Research Collaborative for Health | <1 mi |
| Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) | — | Mirum Pharmaceuticals, Inc. | <1 mi |
| Primary Sclerosing Cholangitis in Children | — | Arbor Research Collaborative for Health | <1 mi |
| Danazol for Treatment of Cytopenias in Patients With Cirrhosis | Phase 2 | University of Southern California | <1 mi |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Phase 2 | Mirum Pharmaceuticals, Inc. | <1 mi |
| National Liver Cancer Screening Trial | Phase 4 | University of Texas Southwestern Medical Center | <1 mi |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase 1 | Alnylam Pharmaceuticals | <1 mi |
| Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations | Phase 1 | Tyra Biosciences, Inc | <1 mi |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Phase 1 | Angiex, Inc. | <1 mi |
| AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | Phase 1 | University of Southern California | <1 mi |
| DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Phase 2 | DualityBio Inc. | <1 mi |
| Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Phase 1 | Nammi Therapeutics Inc | <1 mi |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | Phase 1 | Jonsson Comprehensive Cancer Center | <1 mi |
| Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | N/A | Cedars-Sinai Medical Center | <1 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | <1 mi |
| Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases | Phase 2 | Kamya Sankar | <1 mi |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Phase 2 | AstraZeneca | <1 mi |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | Phase 1/2 | AstraZeneca | <1 mi |
| Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots | — | University of Southern California | <1 mi |
| A Study of MGC026 in Participants With Advanced Solid Tumors | Phase 1 | MacroGenics | <1 mi |
| SIRT With Tremelimumab and Durvalumab for Resectable HCC | Phase 1 | Jiping Wang, MD, PhD | <1 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | 5 mi |
| Hepatitis C Tracker Study | N/A | University of Southern California | 7 mi |
| A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) | — | Target PharmaSolutions, Inc. | 9 mi |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Phase 2 | Altimmune, Inc. | 9 mi |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Phase 2 | Replimune Inc. | 9 mi |
| Veteran-Centered Care for Advanced Liver Disease (Vet-CALD) | N/A | VA Office of Research and Development | 11 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | 11 mi |
| Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | — | HistoSonics, Inc. | 14 mi |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | Phase 2 | Delcath Systems Inc. | 14 mi |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | 14 mi |
| Congenital Muscle Disease Study of Patient and Family Reported Medical Information | — | Cure CMD | 15 mi |
| Early Detection of Advanced Adenomas and Colorectal Cancer | — | City of Hope Medical Center | 16 mi |
| A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | Phase 1 | SEED Therapeutics, Inc. | 16 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | 16 mi |
| A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | Phase 2/3 | AbbVie | 16 mi |
| A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma | — | City of Hope Medical Center | 16 mi |
| An Exosomal miRNA-based Liquid Biopsy for ICC Detection | — | City of Hope Medical Center | 16 mi |
| Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases | — | City of Hope Medical Center | 16 mi |
| A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer | — | City of Hope Medical Center | 16 mi |
| Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer | Phase 2 | City of Hope Medical Center | 16 mi |
| T-Cell Therapy (ECT204) in Adults With Advanced HCC | Phase 1/2 | Eureka Therapeutics Inc. | 16 mi |
| An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer | — | City of Hope Medical Center | 16 mi |
| Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma. | — | City of Hope Medical Center | 16 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection | Phase 1 | GigaGen, Inc. | 20 mi |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Eccogene | 20 mi |
| A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine | N/A | Southern California Institute for Research and Education | 20 mi |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Phase 1 | Gilead Sciences | 20 mi |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011 | Phase 1 | IDBiologics, Inc. | 20 mi |
| Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus | Phase 1/2 | Gilead Sciences | 24 mi |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | 29 mi |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial | Phase 1/2 | National Cancer Institute (NCI) | 29 mi |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | Phase 3 | NRG Oncology | 29 mi |
| Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | N/A | ABK Biomedical | 29 mi |
| Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers | N/A | University of California, Irvine | 29 mi |
| Combination of TATE and PD-1 Inhibitor in Liver Cancer | Phase 2 | Teclison Ltd. | 29 mi |
| Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | Phase 2 | University of California, Irvine | 29 mi |
| Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | Phase 2 | University of California, Irvine | 29 mi |
| TATE and Pembrolizumab (MK3475) in mCRC and NSCLC | Phase 2 | Teclison Ltd. | 29 mi |
| Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Phase 3 | Disc Medicine, Inc | 31 mi |
| A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | Phase 1 | X4 Pharmaceuticals | 32 mi |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Phase 3 | Crinetics Pharmaceuticals Inc. | 35 mi |
| Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | Phase 2 | Shionogi | 36 mi |
| California MEPS Hub | N/A | University of California, Los Angeles | 49 mi |